Close

Biogen (BIIB) & Samsung Bioepis Co. Report Joint Analysis Results of Anti-TNF Biosimilars BENEPALI (etanercept), FLIXABI (infliximab) & IMRALDI (adalimumab) at EULAR 2018

June 13, 2018 8:19 AM EDT Send to a Friend
Samsung Bioepis Co., Ltd. and Biogen (NASDAQ : BIIB) today announced pooled analysis results of three anti-tumor necrosis factor (anti-TNF) ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login